Effectiveness and safety of intravenous immunoglobulin for peripheral neuropathy in EGPA patients: a retrospective study.

Autor: Fasano C; Department of Experimental and Clinical Medicine, University of Firenze, Firenze, Italy. carla.fasano@unifi.it., Bettiol A; Department of Experimental and Clinical Medicine, University of Firenze, Firenze, Italy., Vastola M; Department of Neurology 2, Careggi University Hospital, 50134, Florence, Italy., Lotti A; Department of Neurology 2, Careggi University Hospital, 50134, Florence, Italy., Malandrino D; Department of Experimental and Clinical Medicine, University of Firenze, Firenze, Italy., Mattioli I; Department of Experimental and Clinical Medicine, University of Firenze, Firenze, Italy., Massacesi L; Department of Neurology 2, Careggi University Hospital, 50134, Florence, Italy., Emmi G; Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy.; Clinical Medicine and Rheumatology Unit, Cattinara University Hospital, Trieste, Italy.; Centre for Inflammatory Diseases, Monash University Department of Medicine, Monash Medical Centre, Melbourne, Australia., Barilaro A; Department of Neurology 2, Careggi University Hospital, 50134, Florence, Italy., Silvestri E; Department of Experimental and Clinical Medicine, University of Firenze, Firenze, Italy.
Jazyk: angličtina
Zdroj: Journal of neurology [J Neurol] 2024 Dec 12; Vol. 272 (1), pp. 13. Date of Electronic Publication: 2024 Dec 12.
DOI: 10.1007/s00415-024-12731-4
Abstrakt: Eosinophilic granulomatosis with polyangiitis (EGPA) is a chronic inflammatory disease belonging to the spectrum of small-vessel vasculitis associated with the presence of anti-neutrophil cytoplasmic antibodies (ANCAs), also characterized by eosinophilic infiltration of target organs. Peripheral neuropathy (PN) affects about 2/3 of the patients as a presenting symptom and typically represents a vasculitic involvement. A few studies have addressed the role of intravenous immunoglobulin (IVIg) for the treatment of PN in EGPA. This monocentric retrospective study aims at assessing the effectiveness and safety of IVIg in patients with PN as the main acute manifestation at EGPA onset. The treatment with IVIg appears to be effective in inducing sustained remission, reducing the risk of relapses and improving the long-term disability due to its effects on PN.
Competing Interests: Declarations. Conflict of interest: On behalf of all authors, the corresponding author states that there is no conflict of interest.
(© 2024. Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: